<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>6 Locally Advanced Cancer | GI Surgical Oncology</title>
  <meta name="description" content="Orientation Manual for GI Surgical Oncology Service" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="6 Locally Advanced Cancer | GI Surgical Oncology" />
  <meta property="og:type" content="book" />
  
  
  <meta property="og:description" content="Orientation Manual for GI Surgical Oncology Service" />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="6 Locally Advanced Cancer | GI Surgical Oncology" />
  
  <meta name="twitter:description" content="Orientation Manual for GI Surgical Oncology Service" />
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="localized.html"/>
<link rel="next" href="definitive-chemort.html"/>
<script src="libs/header-attrs-2.11/header-attrs.js"></script>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li>GI Surgical Oncology</li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="Intro.html"><a href="Intro.html"><i class="fa fa-check"></i><b>1</b> Overview</a>
<ul>
<li class="chapter" data-level="1.1" data-path="Intro.html"><a href="Intro.html#absences"><i class="fa fa-check"></i><b>1.1</b> Absences</a></li>
<li class="chapter" data-level="1.2" data-path="Intro.html"><a href="Intro.html#communication"><i class="fa fa-check"></i><b>1.2</b> Communication</a></li>
<li class="chapter" data-level="1.3" data-path="Intro.html"><a href="Intro.html#inpatients"><i class="fa fa-check"></i><b>1.3</b> Inpatients</a></li>
<li class="chapter" data-level="1.4" data-path="Intro.html"><a href="Intro.html#er-admits"><i class="fa fa-check"></i><b>1.4</b> ER admits</a></li>
<li class="chapter" data-level="1.5" data-path="Intro.html"><a href="Intro.html#medical-records"><i class="fa fa-check"></i><b>1.5</b> Medical Records</a></li>
<li class="chapter" data-level="1.6" data-path="Intro.html"><a href="Intro.html#operative-logs"><i class="fa fa-check"></i><b>1.6</b> Operative Logs</a></li>
<li class="chapter" data-level="1.7" data-path="Intro.html"><a href="Intro.html#case-assignment"><i class="fa fa-check"></i><b>1.7</b> Case Assignment</a></li>
<li class="chapter" data-level="1.8" data-path="Intro.html"><a href="Intro.html#clinic"><i class="fa fa-check"></i><b>1.8</b> Clinic</a></li>
<li class="chapter" data-level="1.9" data-path="Intro.html"><a href="Intro.html#work-hours"><i class="fa fa-check"></i><b>1.9</b> Work Hours</a></li>
</ul></li>
<li class="part"><span><b>Inpatient</b></span></li>
<li class="chapter" data-level="2" data-path="cmc-inpatient.html"><a href="cmc-inpatient.html"><i class="fa fa-check"></i><b>2</b> CMC – Inpatient</a></li>
<li class="chapter" data-level="3" data-path="staging.html"><a href="staging.html"><i class="fa fa-check"></i><b>3</b> Staging</a></li>
<li class="chapter" data-level="4" data-path="superficial.html"><a href="superficial.html"><i class="fa fa-check"></i><b>4</b> Superficial Esophageal Cancer</a>
<ul>
<li class="chapter" data-level="4.1" data-path="superficial.html"><a href="superficial.html#emr"><i class="fa fa-check"></i><b>4.1</b> Endscopic Mucosal Resection (EMR)</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="localized.html"><a href="localized.html"><i class="fa fa-check"></i><b>5</b> Localized Tumors</a>
<ul>
<li class="chapter" data-level="5.1" data-path="localized.html"><a href="localized.html#t1b-tumors"><i class="fa fa-check"></i><b>5.1</b> T1b Tumors</a></li>
<li class="chapter" data-level="5.2" data-path="localized.html"><a href="localized.html#t2n0-tumors"><i class="fa fa-check"></i><b>5.2</b> T2N0 Tumors</a></li>
<li class="chapter" data-level="5.3" data-path="localized.html"><a href="localized.html#staging-of-t2n0-tumors"><i class="fa fa-check"></i><b>5.3</b> Staging of T2N0 Tumors</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="locally_advanced.html"><a href="locally_advanced.html"><i class="fa fa-check"></i><b>6</b> Locally Advanced Cancer</a>
<ul>
<li class="chapter" data-level="6.1" data-path="locally_advanced.html"><a href="locally_advanced.html#trimodality"><i class="fa fa-check"></i><b>6.1</b> Trimodality Therapy</a>
<ul>
<li class="chapter" data-level="6.1.1" data-path="locally_advanced.html"><a href="locally_advanced.html#neoadjuvant-chemort-for-scca"><i class="fa fa-check"></i><b>6.1.1</b> Neoadjuvant chemoRT for SCCA</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="locally_advanced.html"><a href="locally_advanced.html#chemort-vs-trimodality-therapy"><i class="fa fa-check"></i><b>6.2</b> ChemoRT vs Trimodality therapy</a>
<ul>
<li class="chapter" data-level="6.2.1" data-path="locally_advanced.html"><a href="locally_advanced.html#neoadjuvant-chemotheraphy-followed-by-surgery"><i class="fa fa-check"></i><b>6.2.1</b> Neoadjuvant chemotheraphy followed by surgery</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="locally_advanced.html"><a href="locally_advanced.html#ge-junction"><i class="fa fa-check"></i><b>6.3</b> GE Junction</a></li>
<li class="chapter" data-level="6.4" data-path="locally_advanced.html"><a href="locally_advanced.html#induction-chemotherapy-followed-by-chemort"><i class="fa fa-check"></i><b>6.4</b> Induction chemotherapy followed by chemoRT</a></li>
<li class="chapter" data-level="6.5" data-path="locally_advanced.html"><a href="locally_advanced.html#postoperative-chemoradiation"><i class="fa fa-check"></i><b>6.5</b> Postoperative chemoradiation</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="definitive-chemort.html"><a href="definitive-chemort.html"><i class="fa fa-check"></i><b>7</b> Definitive ChemoRT</a>
<ul>
<li class="chapter" data-level="7.1" data-path="definitive-chemort.html"><a href="definitive-chemort.html#phase-ii-studies"><i class="fa fa-check"></i><b>7.1</b> Phase II Studies</a></li>
<li class="chapter" data-level="7.2" data-path="definitive-chemort.html"><a href="definitive-chemort.html#chemort-vs-trimodality-therapy-1"><i class="fa fa-check"></i><b>7.2</b> ChemoRT vs Trimodality therapy</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="radiation-for-esophageal-cancer.html"><a href="radiation-for-esophageal-cancer.html"><i class="fa fa-check"></i><b>8</b> Radiation for esophageal cancer</a>
<ul>
<li class="chapter" data-level="8.1" data-path="radiation-for-esophageal-cancer.html"><a href="radiation-for-esophageal-cancer.html#salvage-esophagectomy"><i class="fa fa-check"></i><b>8.1</b> Salvage esophagectomy</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="surgery.html"><a href="surgery.html"><i class="fa fa-check"></i><b>9</b> Surgery</a>
<ul>
<li class="chapter" data-level="9.0.1" data-path="surgery.html"><a href="surgery.html#preoperative-evaluation"><i class="fa fa-check"></i><b>9.0.1</b> Preoperative Evaluation</a></li>
<li class="chapter" data-level="9.1" data-path="surgery.html"><a href="surgery.html#minimally-invasive-esophagectomy"><i class="fa fa-check"></i><b>9.1</b> Minimally-invasive Esophagectomy</a></li>
<li class="chapter" data-level="9.2" data-path="surgery.html"><a href="surgery.html#transthoracic"><i class="fa fa-check"></i><b>9.2</b> Transthoracic</a></li>
<li class="chapter" data-level="9.3" data-path="surgery.html"><a href="surgery.html#transhiatal"><i class="fa fa-check"></i><b>9.3</b> Transhiatal</a></li>
<li class="chapter" data-level="9.4" data-path="surgery.html"><a href="surgery.html#three-hole"><i class="fa fa-check"></i><b>9.4</b> Three-hole</a></li>
<li class="chapter" data-level="9.5" data-path="surgery.html"><a href="surgery.html#extended-lymphadenectomy"><i class="fa fa-check"></i><b>9.5</b> Extended lymphadenectomy</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="eso_metastatic.html"><a href="eso_metastatic.html"><i class="fa fa-check"></i><b>10</b> Metastatic</a>
<ul>
<li class="chapter" data-level="10.1" data-path="eso_metastatic.html"><a href="eso_metastatic.html#palliative-radiation"><i class="fa fa-check"></i><b>10.1</b> Palliative radiation</a></li>
<li class="chapter" data-level="10.2" data-path="eso_metastatic.html"><a href="eso_metastatic.html#chemoradiation-vs-chemotherapy-in-stage-iv"><i class="fa fa-check"></i><b>10.2</b> Chemoradiation vs chemotherapy in Stage IV</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="stents-for-malignant-disease.html"><a href="stents-for-malignant-disease.html"><i class="fa fa-check"></i><b>11</b> Stents for malignant disease</a></li>
<li class="chapter" data-level="12" data-path="eso_surveillance.html"><a href="eso_surveillance.html"><i class="fa fa-check"></i><b>12</b> Surveillance</a>
<ul>
<li class="chapter" data-level="12.1" data-path="eso_surveillance.html"><a href="eso_surveillance.html#t1a-treated-with-endoscopic-resection"><i class="fa fa-check"></i><b>12.1</b> T1a treated with endoscopic resection</a></li>
<li class="chapter" data-level="12.2" data-path="eso_surveillance.html"><a href="eso_surveillance.html#tib-treated-with-endoscoic-resection"><i class="fa fa-check"></i><b>12.2</b> Tib treated with endoscoic resection</a></li>
<li class="chapter" data-level="12.3" data-path="eso_surveillance.html"><a href="eso_surveillance.html#t1b-treated-with-esophagectomy"><i class="fa fa-check"></i><b>12.3</b> T1b treated with esophagectomy</a></li>
<li class="chapter" data-level="12.4" data-path="eso_surveillance.html"><a href="eso_surveillance.html#stage-ii-or-iii-treated-with-chemoradiation."><i class="fa fa-check"></i><b>12.4</b> Stage II or III treated with chemoradiation.</a></li>
<li class="chapter" data-level="12.5" data-path="eso_surveillance.html"><a href="eso_surveillance.html#locally-advanced-treated-with-trimodality-therapy"><i class="fa fa-check"></i><b>12.5</b> Locally-advanced treated with trimodality therapy</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="eso_survivorship.html"><a href="eso_survivorship.html"><i class="fa fa-check"></i><b>13</b> Survivorship</a>
<ul>
<li class="chapter" data-level="13.1" data-path="eso_survivorship.html"><a href="eso_survivorship.html#nutritional-consequences"><i class="fa fa-check"></i><b>13.1</b> Nutritional consequences</a></li>
<li class="chapter" data-level="13.2" data-path="eso_survivorship.html"><a href="eso_survivorship.html#cardiac-toxicity-of-radiation"><i class="fa fa-check"></i><b>13.2</b> Cardiac toxicity of radiation</a></li>
</ul></li>
<li class="part"><span><b>Gastric Cancer</b></span></li>
<li class="chapter" data-level="14" data-path="overview.html"><a href="overview.html"><i class="fa fa-check"></i><b>14</b> Overview</a></li>
<li class="chapter" data-level="15" data-path="gast_superficial.html"><a href="gast_superficial.html"><i class="fa fa-check"></i><b>15</b> Superficial</a></li>
<li class="chapter" data-level="16" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html"><i class="fa fa-check"></i><b>16</b> Locally-Advanced Gastric</a>
<ul>
<li class="chapter" data-level="16.1" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html#preoperative-chemotherapy"><i class="fa fa-check"></i><b>16.1</b> Preoperative Chemotherapy</a></li>
<li class="chapter" data-level="16.2" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html#postoperative-chemotherapy"><i class="fa fa-check"></i><b>16.2</b> Postoperative chemotherapy</a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="locally-advanced-gastric-ca.html"><a href="locally-advanced-gastric-ca.html"><i class="fa fa-check"></i><b>17</b> Locally Advanced Gastric Ca</a>
<ul>
<li class="chapter" data-level="17.1" data-path="locally-advanced-gastric-ca.html"><a href="locally-advanced-gastric-ca.html#postoperative-chemoradiation-1"><i class="fa fa-check"></i><b>17.1</b> Postoperative chemoradiation</a></li>
<li class="chapter" data-level="17.2" data-path="locally-advanced-gastric-ca.html"><a href="locally-advanced-gastric-ca.html#preoperative-chemoradiation"><i class="fa fa-check"></i><b>17.2</b> Preoperative chemoradiation</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="chapter" data-level="18" data-path="neoadjuvant-chemotherapy-for-colon-cancer.html"><a href="neoadjuvant-chemotherapy-for-colon-cancer.html"><i class="fa fa-check"></i><b>18</b> Neoadjuvant Chemotherapy for colon cancer</a></li>
<li class="chapter" data-level="19" data-path="extended-node-dissection-for-colon-cancer.html"><a href="extended-node-dissection-for-colon-cancer.html"><i class="fa fa-check"></i><b>19</b> Extended Node dissection for colon cancer</a></li>
<li class="divider"></li>
<li><a href="mailto:jonathan.salo@atriumhealth.org">Feedback and Updates</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">GI Surgical Oncology</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="locally_advanced" class="section level1" number="6">
<h1><span class="header-section-number">6</span> Locally Advanced Cancer</h1>
<p>Tumors that are T2N<sup>+</sup>M0 or T3NxM0 are considered locally-advanced. The high rate of failure with surgery alone has led to development of adjunctive therapies.</p>
<div id="trimodality" class="section level2" number="6.1">
<h2><span class="header-section-number">6.1</span> Trimodality Therapy</h2>
<p>Trimodality therapy consists of chemoradiation followed by surgery.</p>
<p>CROSS trial randomized 364 patients with resectable esophageal and gastroesophageal junction tumors (75% adenocarcinoma) to neoadjuvant chemoradiation consisting of 4,140 cGy of radiation with concurrent carboplatin and paclitaxel or surgery alone.<span class="citation">(<a href="#ref-vanhagen2074" role="doc-biblioref">van Hagen et al. 2012</a>)</span> Clinical node-positive disease was present in 16%. Pathologic complete response was seen in 23% of adenocarcinoma and 49% of squamous cell carcinomas. Median overall survival was 49 months after trimodality vs 24 months after surgery alone (p=0.003). Squamous cell carcinomas appeared to have particular benefit, with a hazard ratio of 0.42 for squamous cell vs 0.74 for adenocarcinoma. Median survival was improved for adenocarcinoma from 27.1 months to 43.2 months, but the median survival for squamous cell increased from 27.1months to 81.6 months for squamous cell. Rate of R0 resection was higher with chemoradiation (92% vs 69% p&lt;0.001) andlocal recurrence rates lower (14% vs 34% P&lt;0.001), and peritoneal recurrence lower (4% vs 14% P&lt;0.001). Despite the relatively low dose of radiation, in-field recurrences were less than 5%. The primary cause of failure was distant disease (31%) and local/regional failure (14%).<span class="citation">(<a href="#ref-oppedijk385" role="doc-biblioref">Oppedijk et al. 2014</a>)</span></p>
<p>Alternative to carbotaxol is FOLFOX (SOG trial <span class="citation">(<a href="#ref-leichman4555" role="doc-biblioref">Leichman et al. 2011</a>)</span>)</p>
<p>Ogoing PROTECT trial ompares FOLFOX to paclitaxel and carbo <span class="citation">(<a href="#ref-messager318" role="doc-biblioref">Messager et al. 2016</a>)</span></p>
<div id="neoadjuvant-chemort-for-scca" class="section level3" number="6.1.1">
<h3><span class="header-section-number">6.1.1</span> Neoadjuvant chemoRT for SCCA</h3>
<p>NeoCRTEC5010 <span class="citation">(<a href="#ref-yang2796" role="doc-biblioref">Yang et al. 2018</a>)</span> <!--- JCO 2018 ---></p>
<p>Meta-abalysis of chemoRT vs chemo <span class="citation">(<a href="#ref-zhaoe0202185" role="doc-biblioref">Zhao et al. 2018</a>)</span></p>
</div>
</div>
<div id="chemort-vs-trimodality-therapy" class="section level2" number="6.2">
<h2><span class="header-section-number">6.2</span> ChemoRT vs Trimodality therapy</h2>
<p>The sensitivity of squamous cell carcinoma of the esophagus to chemoradiation has raised the question whether</p>
<p>Stahl Locally advanced squamous cell carcinoma randomized to induction chemotherapy (cisplatin, etopiside, 5FU with leuocovrin) followed by chemoradiation (4000cGy with concurrent ciplatin and etopiside) followed by surgery compared with induction chemotherapy followed by chemoradiation (6400cGy with concurrent cisplatin and etopiside).<span class="citation">(<a href="#ref-stahl2310" role="doc-biblioref">Stahl et al. 2005</a>)</span> progression-free survival was better in the trimodality group (64.3% vs 40.7%) Treatment-related morality was substantial in the surgery arm (13% vs 4%). This would be considered an excessive rate of operative mortality by modern standards. Unsurprisingly, there was no difference in overall survival between groups, in part because the surgical group had an excess 9% mortality rate from treatment. Two-year survival in the surgery arm was 40% vs 35% in the definitive chemoradiation arm. <span class="citation">(<a href="#ref-stahl4530" role="doc-biblioref"><strong>stahl4530?</strong></a>)</span></p>
<p>In the French FFCD trial, 444 patients with carcinoma of the esophagus (90% squamous cell) were treated with two cycles of 5-FU and cisplatin with concurrent radiation.<span class="citation">(<a href="#ref-bedenne1160" role="doc-biblioref">Bedenne et al. 2007</a>)</span> Patients with a partial or complete clinical response to chemoradiation were randomized to either surgery or a boost of radiation. Patients who did not respond to chemoradiation were treated with surgery and were eliminated from the study. Only 259 of the original 444 patients (59%) went on to randomization, with the remainder (those not responding to chemoradiation) treated with surgery. Of the randomized group, median survival was 17.7months in the surgery arm versus 19.3months in the definitive chemoradiation arm. Like the Stahl study, treatment-related mortality in the surgical arm was high (9% versus 1%).</p>
<div id="neoadjuvant-chemotheraphy-followed-by-surgery" class="section level3" number="6.2.1">
<h3><span class="header-section-number">6.2.1</span> Neoadjuvant chemotheraphy followed by surgery</h3>
<p>POET Trial (Pre-Operative therapy in Esophageal adenocarcinoma Trial) treated patients with adenocarcinoma of the gastroesophageal junction with either neoadjuvant chemotherapy (5-FU, leucovorin, cisplatin) followed by surgery or induction chemotherapy with the same agents, followed by chemoradiation (4000cGy with concurrent cisplatin and etoposide). The study failed to meet its accrual goal, but there was a suggestion of improved 3-year survival with preoperative chemoradiation (47.4% vs 27.7% <em>p</em>=0.07) as well as improved local control (76.5% vs 59%). In addition, chemoradiation was associated with a higher pathologic complete response rate (15.6% vs 2%)<span class="citation">(<a href="#ref-stahl851" role="doc-biblioref">Stahl et al. 2009</a>)</span>. A meta-analysis of 33 randomized trials further suggested a greater benefit from neoadjuvant chemoradiation followed by surgery compared with neoadjuvant chemotherapy followed by surgery<span class="citation">(<a href="#ref-pasquali481" role="doc-biblioref">Pasquali et al. 2017</a>)</span> and a similar meta-analysis <span class="citation">(<a href="#ref-sjoquist681" role="doc-biblioref">Sjoquist et al. 2011</a>)</span></p>
<p>#Active Surveillance</p>
<p>EGD is poor predictor of pCR <span class="citation">(<a href="#ref-sarkaria764" role="doc-biblioref">Sarkaria et al. 2009</a>)</span></p>
</div>
</div>
<div id="ge-junction" class="section level2" number="6.3">
<h2><span class="header-section-number">6.3</span> GE Junction</h2>
<p><span class="citation">(<a href="#ref-siewert260" role="doc-biblioref">Siewert, Stein, and Feith 2006</a>)</span></p>
</div>
<div id="induction-chemotherapy-followed-by-chemort" class="section level2" number="6.4">
<h2><span class="header-section-number">6.4</span> Induction chemotherapy followed by chemoRT</h2>
<p>See NCCN pages M-25 and M-26</p>
<p>Stahl <span class="citation">(<a href="#ref-stahl851" role="doc-biblioref">Stahl et al. 2009</a>)</span> randomized patients to preoperative chemotherapy (A) vs preoperative chemotherapy followed by preoperative chemoradiation (B). Higher pcR rate in arm B (15.6% vs 2%) and ypN0 resection (64.4% vs 37.7%).</p>
</div>
<div id="postoperative-chemoradiation" class="section level2" number="6.5">
<h2><span class="header-section-number">6.5</span> Postoperative chemoradiation</h2>
<p>Intergroup-0116 <span class="citation">(<a href="#ref-macdonald725" role="doc-biblioref">Macdonald et al. 2001</a>)</span> <span class="citation">(<a href="#ref-smalley2327" role="doc-biblioref">Smalley et al. 2012</a>)</span> treated 556 patients with adenocarcinoma of the stomach or GE junction with surgery along vs surgery followed by postoperative chemoradiation. After a median followup of over 5 years, median overall survival iin the surgery alone group was 27 months vs 36 months in the postoperative chemoradiation group (p=0.005) Decrease in local failure as the first site of failure in the chemoradiation group (19% versus 29%).</p>
<p>Chemoradiation afte resectdion of GE junction tumors <span class="citation">(<a href="#ref-kofoed26" role="doc-biblioref">Kofoed et al. 2012</a>)</span> among a group of 211 patients with GE junction adenocarcinoma with positive lymph nodes with improved 3-year disease-free survival (37% s 24%).</p>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body hanging-indent">
<div id="ref-bedenne1160" class="csl-entry">
Bedenne, Laurent, Pierre Michel, Olivier Bouché, Chantal Milan, Christophe Mariette, Thierry Conroy, Denis Pezet, et al. 2007. <span>“Chemoradiation Followed by Surgery Compared with Chemoradiation Alone in Squamous Cancer of the Esophagus: <span>FFCD</span> 9102.”</span> <em>J Clin Oncol</em> 25 (10): 1160–68. <a href="https://doi.org/10.1200/JCO.2005.04.7118">https://doi.org/10.1200/JCO.2005.04.7118</a>.
</div>
<div id="ref-kofoed26" class="csl-entry">
Kofoed, S. C., A. Muhic, L. Baeksgaard, M. Jendresen, J. Gustafsen, J. Holm, L. Bardram, B. Brandt, J. Brenø, and L. B. Svendsen. 2012. <span>“Survival After Adjuvant Chemoradiotherapy or Surgery Alone in Resectable Adenocarcinoma at the Gastro-Esophageal Junction.”</span> <em>Scand J Surg</em> 101 (1): 26–31. <a href="https://doi.org/10.1177/145749691210100106">https://doi.org/10.1177/145749691210100106</a>.
</div>
<div id="ref-leichman4555" class="csl-entry">
Leichman, Lawrence P., Bryan H. Goldman, Pierre O. Bohanes, Heinz J. Lenz, Charles R. Thomas, Kevin G. Billingsley, Christopher L. Corless, et al. 2011. <span>“S0356: A Phase <span>II</span> Clinical and Prospective Molecular Trial with Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients with Esophageal Adenocarcinoma.”</span> <em>J Clin Oncol</em> 29 (34): 4555–60. <a href="https://doi.org/10.1200/JCO.2011.36.7490">https://doi.org/10.1200/JCO.2011.36.7490</a>.
</div>
<div id="ref-macdonald725" class="csl-entry">
Macdonald, J. S., S. R. Smalley, J. Benedetti, S. A. Hundahl, N. C. Estes, G. N. Stemmermann, D. G. Haller, et al. 2001. <span>“Chemoradiotherapy After Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction.”</span> <em>N Engl J Med</em> 345 (10): 725–30. <a href="https://doi.org/10.1056/NEJMoa010187">https://doi.org/10.1056/NEJMoa010187</a>.
</div>
<div id="ref-messager318" class="csl-entry">
Messager, Mathieu, Xavier Mirabel, Emmanuelle Tresch, Amaury Paumier, Véronique Vendrely, Laetitia Dahan, Olivier Glehen, et al. 2016. <span>“Preoperative Chemoradiation with Paclitaxel-Carboplatin or with Fluorouracil-Oxaliplatin-Folinic Acid (<span>FOLFOX</span>) for Resectable Esophageal and Junctional Cancer: The <span>PROTECT</span>-1402, Randomized Phase 2 Trial.”</span> <em>BMC Cancer</em> 16 (May): 318. <a href="https://doi.org/10.1186/s12885-016-2335-9">https://doi.org/10.1186/s12885-016-2335-9</a>.
</div>
<div id="ref-oppedijk385" class="csl-entry">
Oppedijk, Vera, Ate van der Gaast, Jan J. B. van Lanschot, Pieter van Hagen, Rob van Os, Caroline M. van Rij, Maurice J. van der Sangen, et al. 2014. <span>“Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the <span>CROSS</span> Trials.”</span> <em>J Clin Oncol</em> 32 (5): 385–91. <a href="https://doi.org/10.1200/JCO.2013.51.2186">https://doi.org/10.1200/JCO.2013.51.2186</a>.
</div>
<div id="ref-pasquali481" class="csl-entry">
Pasquali, Sandro, Guang Yim, Ravinder S. Vohra, Simone Mocellin, Donald Nyanhongo, Paul Marriott, Ju Ian Geh, and Ewen A. Griffiths. 2017. <span>“Survival <span>After Neoadjuvant</span> and <span>Adjuvant Treatments Compared</span> to <span>Surgery Alone</span> for <span>Resectable Esophageal Carcinoma</span>: <span>A Network Meta</span>-Analysis.”</span> <em>Ann Surg</em> 265 (3): 481–91. <a href="https://doi.org/10.1097/SLA.0000000000001905">https://doi.org/10.1097/SLA.0000000000001905</a>.
</div>
<div id="ref-sarkaria764" class="csl-entry">
Sarkaria, Inderpal S., Nabil P. Rizk, Manjit S. Bains, Laura H. Tang, David H. Ilson, Bruce I. Minsky, and Valerie W. Rusch. 2009. <span>“Post-Treatment Endoscopic Biopsy Is a Poor-Predictor of Pathologic Response in Patients Undergoing Chemoradiation Therapy for Esophageal Cancer.”</span> <em>Ann Surg</em> 249 (5): 764–67. <a href="https://doi.org/10.1097/SLA.0b013e3181a38e9e">https://doi.org/10.1097/SLA.0b013e3181a38e9e</a>.
</div>
<div id="ref-siewert260" class="csl-entry">
Siewert, J. R., H. J. Stein, and M. Feith. 2006. <span>“Adenocarcinoma of the Esophago-Gastric Junction.”</span> <em>Scand J Surg</em> 95 (4): 260–69. <a href="https://doi.org/10.1177/145749690609500409">https://doi.org/10.1177/145749690609500409</a>.
</div>
<div id="ref-sjoquist681" class="csl-entry">
Sjoquist, Katrin M., Bryan H. Burmeister, B. Mark Smithers, John R. Zalcberg, R. John Simes, Andrew Barbour, Val Gebski, and Australasian Gastro-Intestinal Trials Group. 2011. <span>“Survival After Neoadjuvant Chemotherapy or Chemoradiotherapy for Resectable Oesophageal Carcinoma: An Updated Meta-Analysis.”</span> <em>Lancet Oncol</em> 12 (7): 681–92. <a href="https://doi.org/10.1016/S1470-2045(11)70142-5">https://doi.org/10.1016/S1470-2045(11)70142-5</a>.
</div>
<div id="ref-smalley2327" class="csl-entry">
Smalley, Stephen R., Jacqueline K. Benedetti, Daniel G. Haller, Scott A. Hundahl, Norman C. Estes, Jaffer A. Ajani, Leonard L. Gunderson, et al. 2012. <span>“Updated Analysis of <span>SWOG</span>-Directed Intergroup Study 0116: A Phase <span>III</span> Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection.”</span> <em>J Clin Oncol</em> 30 (19): 2327–33. <a href="https://doi.org/10.1200/JCO.2011.36.7136">https://doi.org/10.1200/JCO.2011.36.7136</a>.
</div>
<div id="ref-stahl2310" class="csl-entry">
Stahl, Michael, Martin Stuschke, Nils Lehmann, Hans-Joachim Meyer, Martin K. Walz, Siegfried Seeber, Bodo Klump, et al. 2005. <span>“Chemoradiation with and Without Surgery in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus.”</span> <em>J Clin Oncol</em> 23 (10): 2310–17. <a href="https://doi.org/10.1200/JCO.2005.00.034">https://doi.org/10.1200/JCO.2005.00.034</a>.
</div>
<div id="ref-stahl851" class="csl-entry">
Stahl, Michael, Martin K. Walz, Martin Stuschke, Nils Lehmann, Hans-Joachim Meyer, Jorge Riera-Knorrenschild, Peter Langer, et al. 2009. <span>“Phase <span>III</span> Comparison of Preoperative Chemotherapy Compared with Chemoradiotherapy in Patients with Locally Advanced Adenocarcinoma of the Esophagogastric Junction.”</span> <em>J Clin Oncol</em> 27 (6): 851–56. <a href="https://doi.org/10.1200/JCO.2008.17.0506">https://doi.org/10.1200/JCO.2008.17.0506</a>.
</div>
<div id="ref-vanhagen2074" class="csl-entry">
van Hagen, P., M. C. Hulshof, J. J. van Lanschot, E. W. Steyerberg, M. I. van Berge Henegouwen, B. P. Wijnhoven, D. J. Richel, et al. 2012. <span>“Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer.”</span> Journal {{Article}}. <em>N Engl J Med</em> 366 (22): 2074–84. <a href="https://doi.org/10.1056/NEJMoa1112088">https://doi.org/10.1056/NEJMoa1112088</a>.
</div>
<div id="ref-yang2796" class="csl-entry">
Yang, Hong, Hui Liu, Yuping Chen, Chengchu Zhu, Wentao Fang, Zhentao Yu, Weimin Mao, et al. 2018. <span>“Neoadjuvant <span>Chemoradiotherapy Followed</span> by <span>Surgery Versus Surgery Alone</span> for <span>Locally Advanced Squamous Cell Carcinoma</span> of the <span>Esophagus</span> (<span>Neocrtec5010</span>): <span>A Phase III Multicenter</span>, <span>Randomized</span>, <span>Open</span>-<span>Label Clinical Trial</span>.”</span> <em>J Clin Oncol</em> 36 (27): 2796–2803. <a href="https://doi.org/10.1200/JCO.2018.79.1483">https://doi.org/10.1200/JCO.2018.79.1483</a>.
</div>
<div id="ref-zhaoe0202185" class="csl-entry">
Zhao, Xin, Yiming Ren, Yong Hu, Naiqiang Cui, Ximo Wang, and Yunfeng Cui. 2018. <span>“Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Cancer of the Esophagus or the Gastroesophageal Junction: <span>A</span> Meta-Analysis Based on Clinical Trials.”</span> <em>PLoS One</em> 13 (8): e0202185. <a href="https://doi.org/10.1371/journal.pone.0202185">https://doi.org/10.1371/journal.pone.0202185</a>.
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="localized.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="definitive-chemort.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["gi_surgonc.pdf", "gi_surgonc.epub"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "section",
"scroll_highlight": true,
"search": true,
"sharing": false
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
